Europe did not ask for this opportunity, says VIB’s Jérôme van Biervliet, but with FDA and the U.S. research funding situation headed into uncertain territory, it needs to use this moment to capitalize on its strengths in research, and address the shortcomings of its business and regulatory systems that have made it hard for biotech to fulfill its potential there. Van Biervliet is managing director of Flanders Institute for Biotechnology (VIB), a key player in the Belgian biotech landscape that has both a research arm and an investment unit.  Ahead of BioCentury’s Bio€quity Europe conference in Bruges, which will discuss how Europe can meet the complexity of this moment, he talked to BioCentury Editor in Chief Simone Fishburn on The BioCentury Show about the landscape unfolding in Europe, as well as where he sees innovation headed.

View full story: https://www.biocentury.com/article/655818

#biotech #biopharma #pharma #LifeScience #ResearchFunding #EuropeanInnovation

00:00 - Introduction
02:03 - VIB’s Mission
07:52 - Europe’s Funding Opportunity
17:37 - Belgium’s Biotech Ecosystem
25:27 - Nanobodies’ Potential